{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-059069","form_type":"8-K","ticker":"TRDA","cik":"0001689375","company_name":"Entrada Therapeutics, Inc.","filed_at":"2022-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.842298+00:00","generated_at":"2026-06-25T18:43:29.821659+00:00","sec_items":["9.01","2.02"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Entrada Q1 net loss $21.7M; announces second candidate ENTR-701 for DM1; IND on track for Q4 2022","bullets":["Q1 2022 net loss of $21.7M vs $8.4M YoY; R&D expenses rose to $15.7M from $6.2M.","Cash, equivalents & marketable securities $263.9M at March 31 (down from $291.1M); runway into H2 2024.","Announced ENTR-701 as second clinical candidate for myotonic dystrophy type 1 (DM1).","On track to submit IND for ENTR-601-44 (Duchenne MD, exon 44 skipping) in Q4 2022.","Preclinical data showed durable exon 44 skipping in NHP biceps for at least 12 weeks after single dose of ENTR-601-44."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-059069","json":"https://secwatch.observer/filing/0001104659-22-059069.json","markdown":"https://secwatch.observer/filing/0001104659-22-059069.md","text":"https://secwatch.observer/filing/0001104659-22-059069.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689375/000110465922059069/0001104659-22-059069-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689375/000110465922059069/tm2215094d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T18:43:29.821659+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}